Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
202.30
-3.10 (-1.51%)
Aug 25, 2026, 3:48 PM EDT - Market open
Axsome Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 776.57 | 638.5 | 385.69 | 270.6 | 50.04 | - | |
Revenue Growth | 56.87% | 65.55% | 42.53% | 440.80% | - | - |
Cost of Revenue | 52.53 | 47.48 | 33.3 | 26.07 | 4.1 | - |
Gross Profit | 724.04 | 591.02 | 352.39 | 244.54 | 45.94 | - |
Selling, General & Admin | 712.67 | 570.6 | 411.36 | 323.12 | 159.25 | 66.65 |
Research & Development | 187.86 | 183.28 | 187.08 | 97.94 | 57.95 | 58.06 |
Amortization of Goodwill & Intangibles | 6.38 | 6.38 | 6.39 | 6.38 | 4.14 | - |
Operating Expenses | 906.9 | 760.25 | 604.83 | 427.44 | 221.34 | 124.71 |
Operating Income | -182.86 | -169.24 | -252.44 | -182.91 | -175.4 | -124.71 |
Interest Expense | -12.88 | -15.93 | -21.58 | -20.03 | -9.66 | -5.7 |
Interest & Investment Income | 7.86 | 9.37 | 15.01 | 13.58 | 2.32 | - |
EBT Excluding Unusual Items | -187.88 | -175.79 | -259.01 | -189.36 | -182.74 | -130.4 |
Merger & Restructuring Charges | - | - | - | - | -1.1 | - |
Other Unusual Items | -3.21 | -7.91 | -28.12 | -48.92 | -3.3 | - |
Pretax Income | -191.09 | -183.7 | -287.13 | -238.28 | -187.13 | -130.4 |
Income Tax Expense | 0.56 | -0.53 | 0.09 | 0.96 | - | - |
Net Income | -191.64 | -183.17 | -287.22 | -239.24 | -187.13 | -130.4 |
Net Income to Common | -191.64 | -183.17 | -287.22 | -239.24 | -187.13 | -130.4 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 51 | 50 | 48 | 45 | 41 | 38 |
Shares Outstanding (Diluted) | 51 | 50 | 48 | 45 | 41 | 38 |
Shares Change | 4.44% | 3.82% | 5.48% | 11.73% | 8.07% | 1.11% |
EPS (Basic) | -3.76 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
EPS (Diluted) | -3.76 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -71.96 | -93.89 | -128.68 | -145.66 | -117.21 | -108.53 |
Free Cash Flow Per Share | -1.41 | -1.89 | -2.69 | -3.21 | -2.88 | -2.88 |
Gross Margin | 93.24% | 92.56% | 91.36% | 90.37% | 91.81% | - |
Operating Margin | -23.55% | -26.51% | -65.45% | -67.59% | -350.54% | - |
Profit Margin | -24.68% | -28.69% | -74.47% | -88.41% | -373.99% | - |
Free Cash Flow Margin | -9.27% | -14.70% | -33.36% | -53.83% | -234.25% | - |
EBITDA | -172.92 | -160.17 | -244.48 | -176.07 | -171 | -124.63 |
EBITDA Margin | -22.27% | -25.09% | -63.39% | -65.07% | - | - |
D&A For EBITDA | 9.94 | 9.06 | 7.96 | 6.83 | 4.4 | 0.08 |
EBIT | -182.86 | -169.24 | -252.44 | -182.91 | -175.4 | -124.71 |
EBIT Margin | -23.55% | -26.51% | -65.45% | -67.59% | - | - |
Revenue as Reported | 776.57 | 638.5 | 385.69 | 270.6 | 50.04 | - |
Advertising Expenses | - | 167.1 | 101.2 | 100.3 | 35.3 | - |